Loading...
XNASCSCI
Market cap7mUSD
Dec 23, Last price  
2.59USD
1D
3.44%
1Q
-31.95%
Name

Aeterna Zentaris Inc

Chart & Performance

D1W1MN
XNAS:CSCI chart
P/E
—
P/S
1.73
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
48.11%
Rev. gr., 5y
-29.81%
Revenues
5m
-18.79%
194,027,434247,389,00041,392,00042,068,00038,478,00063,237,00027,703,00036,053,00033,665,0006,175,00011,000545,000911,000923,00026,881,000532,0003,652,0005,260,0005,640,0004,580,487
Net income
-17m
L-55.25%
010,571,00033,390,000-32,296,000-59,817,000-24,724,000-23,218,000-27,067,000-20,412,0006,815,000-16,564,000-50,143,000-24,959,000-16,796,0004,187,000-6,042,000-5,118,000-8,368,000-37,669,000-16,855,544
CFO
-17m
L+27.43%
10,650,15312,934,0007,957,000-25,530,000-1,272,000-24,138,000-31,120,000-26,243,000-30,815,000-19,984,000-31,082,000-33,844,000-29,010,000-22,913,0006,825,000-10,725,000-4,129,000-8,581,000-13,680,000-17,431,923
Earnings
Mar 25, 2025

Profile

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
URL
https://www.zentaris.com/
IPO date
Dec 19, 1995
Employees
12
Domiciled in
CA
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
4,580
-18.79%
5,640
7.22%
5,260
44.03%
Cost of revenue
22,919
29,123
13,931
Unusual Expense (Income)
NOPBT
(18,338)
(23,483)
(8,671)
NOPBT Margin
Operating Taxes
3
14,942
(109)
Tax Rate
NOPAT
(18,338)
(38,425)
(8,562)
Net income
(16,856)
-55.25%
(37,669)
350.16%
(8,368)
63.50%
Dividends
Dividend yield
Proceeds from repurchase of equity
50,617
BB yield
-30.99%
Debt
Debt current
299
114
130
Long-term debt
1,634
244
192
Deferred revenue
1,536
1,794
1,591
Other long-term liabilities
(119)
10,251
17,728
Net debt
(32,240)
(50,575)
(65,313)
Cash flow
Cash from operating activities
(17,432)
(13,680)
(8,581)
CAPEX
(19)
(11)
(639)
Cash from investing activities
538
(12)
(658)
Cash from financing activities
(154)
(118)
51,037
FCF
(18,438)
(38,449)
(8,575)
Balance
Cash
33,842
50,611
65,300
Long term investments
330
322
335
Excess cash
33,943
50,651
65,372
Stockholders' equity
(72,143)
(59,641)
(41,887)
Invested Capital
104,535
107,533
114,238
ROIC
ROCE
EV
Common stock shares outstanding
4,856
4,856
4,597
Price
7.44
-41.51%
12.72
-64.20%
35.53
-16.50%
Market cap
36,128
-41.51%
61,767
-62.18%
163,331
133.58%
EV
3,888
11,192
98,018
EBITDA
(18,166)
(23,348)
(8,526)
EV/EBITDA
Interest
128
3
21
Interest/NOPBT